Bris­tol My­ers buys out cell ther­a­py part­ner 2sev­en­ty bio

Bris­tol My­ers Squibb will ac­quire its CAR-T cell ther­a­py col­lab­o­ra­tor 2sev­en­ty bio for $286 mil­lion in cash, the com­pa­nies said late Mon­day evening.

Bris­tol My­ers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER